gmp
gmp

Find Approved Neurology Drugs in Clinical Development

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Country filter
    News Type filter
      Company filter
        Product Type filter
          Deal Size filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual BoothBrightest Minds in the CDMO industry - From early Development to Commercial Manufacturing

            Contact the Supplier

            Lead Product(s): Opicapone

            Therapeutic Area: Neurology Product Name: Ongentys

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Bial

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 01, 2020

            Details:

            The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.

            Virtual BoothDevelopment, Manufacturing & Marketing of Pharmaceuticals for Central Nervous System Pathologies.

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Permira Funds

            Deal Size: $1,880.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition September 22, 2020

            Details:

            The Permira funds will support the management’s vision of becoming the leading CNS-focused specialty pharmaceutical platform in Europe through driving the commercialization of Neuraxpharm’s attractive new product pipeline and support further its expansion internationally.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rimegepant Sulfate

            Therapeutic Area: Neurology Product Name: Nurtec ODT

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 14, 2020

            Details:

            NURTEC ODT 75 mg, in placebo-controlled trials, helped to return patients to normal functioning within 60 minutes when used in the acute treatment of migraine and has also been shown to reduce monthly migraine days at the same dose.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Cenobamate

            Therapeutic Area: Neurology Product Name: Xcopri

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Ono Pharmaceutical

            Deal Size: $506.0 million Upfront Cash: $47.0 million

            Deal Type: Licensing Agreement October 13, 2020

            Details:

            SK Biopharmaceuticals will conduct a Phase 3 clinical study for partial-onset seizures in adults in Northeast Asia (Japan, China, and Korea). In addition, SK Biopharmaceuticals has an option for co-promotion with Ono in the Japanese market.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Ozanimod Hydrochloride

            Therapeutic Area: Neurology Product Name: Zeposia

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 07, 2020

            Details:

            ZEPOSIA® (0.92 mg) demonstrated a relative reduction in ARR versus AVONEX® of 48 per cent through one year in the SUNBEAM study and 38 per cent at two years in the RADIANCE study.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Dimethyl Fumarate

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 07, 2020

            Details:

            Glenmark has received final approval by the U.S. FDA for Dimethyl Fumarate Delayed-Release Capsu